There has been steady progress in osteoarthritis (OA) biomarker research in 2016. Several novel biomarkers were identified and new technologies have been developed for measuring existing biomarkers. However, there has been no “quantum leap” this past year and identification of novel early OA biomarkers remains challenging. During the past year, OARSI published a set of recommendations for the use of soluble biomarkers in clinical trials, which is a major step forward in the clinical use of OA biomarkers and bodes well for future OA biomarker development.

visit link


OACTIVEAdmin has blogged 950 posts

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies. More Info

Cookies are small text files held on your computer. Some cookies are required to ensure that the site functions correctly, for this reason we may have already set some cookies. They also allow us to give you the best browsing experience possible and help us understand how you use our site. For more information read our Privacy Policy.